Published online Apr 28, 2023. doi: 10.4329/wjr.v15.i4.89
Peer-review started: November 18, 2022
First decision: February 15, 2023
Revised: March 3, 2023
Accepted: March 30, 2023
Article in press: March 30, 2023
Published online: April 28, 2023
Processing time: 158 Days and 23.6 Hours
Radiomics is a hot topic in the research on customized oncology treatment, efficacy evaluation, and tumor prognosis prediction. To achieve the goal of mining the heterogeneity information within the tumor tissue, the image features concealed within the tumoral images are turned into quantifiable data features. This article primarily describes the research progress of radiomics and clinical-radiomics combined model in the prediction of efficacy, the choice of treatment modality, and survival in transarterial chemoembolization (TACE) and TACE combination therapy for hepatocellular carcinoma.
Core Tip: Hepatic cancer is a highly varied primary liver malignancy, and distinct tumor stages necessitate different techniques to guarantee appropriate therapeutic efficacy. Radiomics is a potential method, which can predict the benefits of patients with different treatment methods and different tumor stages through the obtained potential information of clinical medical imaging that is difficult to identify with the naked eye, and predict the outcome of patients, thereby assisting precision medical decision-making. In this paper, we propose and discuss the possible use of radiomics in the selection of treatment modalities and efficacy prediction for liver cancer.